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Aim: The aim of this study was to evaluate the effects of radiotherapy plus concurrent weekly cisplatin chemotherapy on
the postoperative recurrence of mediastinal lymph node metastases in esophageal cancer patients.
Methods: Ninety-eight patients were randomly enrolled to receive either three-dimensional conformal radiotherapy alone
(group A) or concurrent chemoradiotherapy (group B). A radiation dose of 62–70 Gy/31–35 fractions was delivered to
the recurrent tumor. Furthermore, the patients in group B simultaneously received weekly doses of cisplatin (30 mg/m2),
and the survival outcomes and toxic effects were compared.
Results: The response rate of group B (91.8%) was significantly greater than that of group A (73.5%) (χ2 = 5.765, P = 0.016).
The 1- and 3-year survival rates of group B (85.7% and 46.9%, respectively) were also greater than those of group A (69.4%
and 28.6%, respectively). However, there were no significant differences in the 5-year survival rates. The numbers of
patients who died of distant metastases in groups A and B were 13 (26.5%) and 5 (10.2%), respectively (χ2 = 4.356,
P = 0.036). Acute radiation-related esophagitis and granulocytopenia in group B was frequent. However, intergroup
differences in terms of late toxicity were not significant.
Conclusions: Three-dimensional conformal radiotherapy (3DCRT) is a practical and feasible technique to treat
the recurrence of mediastinal lymph node metastases of postoperative esophageal cancer. In addition,
concurrent chemotherapy can increase local tumor control, decrease the distant metastasis rate, and increase
the long-term survival rate.
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chemotherapyIntroduction
With annual new diagnoses of more than 500,000 pa-
tients, esophageal cancer is the eighth most common
cancer worldwide [1,2]. It is a highly lethal disease,
causing more than 450,000 deaths annually [2]. The inci-
dence of esophageal adenocarcinoma is rapidly rising,* Correspondence: radyoulu@hotmail.com
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reproduction in any medium, provided the orwhereas that of squamous cell carcinoma remains unvaried
in the past few years [1]. Despite accurate preoperative
staging, 25% of patients treated with primary surgery have
positive microscopic resection margins (R1), and the 5-year
survival rate rarely exceeds 40% [3]. Moreover, esophageal
squamous cell carcinoma (ESCC) is more deadly in
developing countries, such as China, with a 5-year survival
rate of only 25% [4]. Although curative esophagectomy with
radical lymph node dissection is the primary treatment for
early-stage ESCC, the 5-year survival rate remains at 30%
[5]. Locoregional recurrence is the major type of failure in. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shown that locoregional recurrence was the most common
reason for treatment failure, in which mediastinal lymph
node metastases accounted for a principal proportion of
locoregional relapse in patients with advanced ESCC [6,7].
Clearly, patients with recurrence present with a relatively
poorer prognosis [8].
Depending on performance status, a number of ad-
vanced ESCC cases have been reported to tolerate
salvage treatment [9,10]. In these patients, the poten-
tial for a cure existed. Despite no possibility for surgi-
cal candidates, radiotherapy, chemotherapy, as well as
chemoradiotherapy each have been demonstrated as
possible salvage therapies for postoperative locoregio-
nal recurrent esophageal carcinoma, with a median
overall survival of 7.09–16.0 months [11-13]. In a
phase II trial, it has been reported that the combin-
ation of radiotherapy (60 Gy/30 fractions) with system-
atic chemotherapy is a safe and effective salvage option
for locorecurrent ESCC [12,14,15]. It is evident that
chemotherapy, radiotherapy, and chemoradiotherapy
each have displayed definitive responses in a large
number of patients with esophageal cancer [16-21]. In
spite of all this evidence, there remain controversies re-
garding the therapeutic strategies and the prognostic risk
factors for locoregional recurrence of esophageal cancer.
Three-dimensional conformal radiation therapy (3-
DCRT) has been characterized to improve dose distribu-
tion, thereby allowing significant increases in the target
dose and decreases in lung and heart doses [11,14]. Wu
and colleagues have reported refinements of the opti-
mized criteria, including the maximum dose and the im-
portant aspects for 3-DCRT [22]. Furthermore, 3-DCRT
has been associated with a higher response rate in pa-
tients with ESCC, in particular for the tremendous con-
trol of mediastinal lymph node metastases [14,20]. ESCC
is one of the most common cancers in China [23]. In
this study, we prospectively analyzed the efficacy of con-
current 3-DCRT and systematic chemotherapy for treat-
ing patients with postoperative recurrence of mediastinal
lymph node metastases of ESCC.
Materials and methods
Patient eligibility
Between January 2002 and June 2003, 98 patients with
histopathologically confirmed advanced locoregional
ESCC from the First Hospital affiliated with North
Sichuan Medical College, P.R. China, were eligible for
inclusion and randomly assigned to the 3-DCRT group
(group A) or the 3-DCRT + chemotherapy group (group
B) using a random number table. All recruited patients
underwent a radical esophagectomy and lymph node
dissection for ESCC with a R0 margin, which was
defined as the microscopic negative margin of theInternational Union Against Cancer (UICC) criteria [24].
The locoregional recurrence was ascribed to anasto-
motic recurrence or locoregional lymph node metastases
with a prerequisition of locoregional mediastinal involve-
ment. Subsequently, normal liver, kidney, and bone
marrow functions were demonstrated by blood tests.
Eligible patients had a good tolerance for radiotherapy
or chemotherapy according to the World Health
Organization performance status of 0 or 1, without a
past history of neoadjuvant or adjuvant chemoradio-
therapy following esophagectomy. The candidates
who underwent neoadjuvant or adjuvant radiotherapy
and/or chemotherapy were excluded from our study.
In addition, those with supraclavicular lymph node
involvement, only anastomotic stoma recurrence, or
hematogenous metastases were ineligible for this
study. The basic and clinical characteristics of the
studied patients are summarized in Table 1. All pa-
tients provided written informed consent. The institu-
tional review board approved the study protocol. The
clinical research was registered and approved by the
ethics committee of the First Hospital affiliated with
North Sichuan Medical College, P.R. China.
Assessment of locoregional mediastinal recurrence
Pretreatment evaluations included complete history,
physical examination, imaging evaluation, and labora-
tory studies. All patients underwent chest X-ray, chest
computed tomography (CT), or magnetic resonance
imaging (MRI), a barium swallow, electrocardiogram
(ECG), esophagoscopy, and ultrasound of the abdomen
and pelvis. Mediastinal lymph node metastases were
confirmed by the presence of a growing irregular mass
by chest CT or MRI. Mediastinal recurrence was character-
ized as both mediastinal lymph node metastases and anas-
tomotic stoma recurrence of ESCC. Of the 98 eligible
patients, 24 were testified as having anastomotic stoma re-
currence by histopathological examinations. Alternatively,
the following criteria were applied to assess the mediastinal
lymph node metastases: the shortest diameter of the suspi-
cious lymph node in the mediastinum was greater than
10 mm; the shortest diameter of the lymph nodes beside
the esophagus, at the corner between the esophagus and
trachea, or at the cardio-diaphragmatic angle was greater
than 5 mm; and several lymph nodes assembled with annu-
lar enhancement.
Radiotherapy and chemotherapy
Four-mm-sectional CT scanning images were obtained
and transferred to the Treatment Planning System (TPS)
for determination of the target volume and the radiation
treatment plan. Gross tumor volume (GTV) included
both the mediastinal lymph node region and the
recurrent anastomotic region. Subsequently, the clinical
Table 1 Patient characteristics
Characteristic Group A Group B χ2 P
(n = 49) (n = 49)
Gender
Male 32 35 0.425 0.514
Female 17 14
KPS 80.5 ± 2.13 81.2 ± 1.71 1.794* 0.076
Age (years)
Median (range) 54 (38–71) 52 (40–69) 1.515* 0.133
Recurrence time (months)
Median (range) 11.4 (6–24) 12.2 (7–23) 1.978* 0.051
Recurrent tumor size (cm3) 9.84 ± 3.32 10.23 ± 4.13 0.515* 0.608
Anatomic recurrence (number) 11 13 0.221 0.638
Postoperative pathological stage
I + II 30 27 0.377 0.538
III + IV 19 22
Recurrence of locoregional lymph node metastases (number)
≤2 38 40 0.251 0.616
>2 11 9
*t value.
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8-mm radial margin and a 3-cm vertical margin from
the GTV. In addition to this definition, CTV was manu-
ally modified to meet the following criteria: 1) To in-
clude the nearest adjacent lymphatic drainage regions of
the meditational lymph node; 2) To include the 2-cm
margin above and below the anastomotic site; 3) To
avoid noncancerous organs such as the thoracic stom-
ach, spine, and vessel wall. The planning tumor volume
(PTV) was defined as the CTV plus an additional 5-mm
margin around the CTV. The organs at risk (OARs),
such as the lungs, heart, spinal cord, and thoracic
stomach, were also evaluated. A linear 6-MV photon ac-
celerator worked as the X-ray source of radiation. The
prescribed dosage for 95% PTV was calculated using
4–6 fields of the coplanar or noncoplanar 3-DCRT plan,
which was determined to be 62–70 Gy/31–35 fractions.
The radiation plan was divided into two phases. Following
a total dose of 46–50 Gy to the CTV, the supplementary
plan of the GTV boost was designed to increase the radi-
ation dose for the macroscopic lesions. Conventional radi-
ation plans were designed and performed with 10 Gy in 5
fractions for 1 week (2 Gy/fraction). The doses for the
OARs were as follows: maximal dose to the spinal cord,
<45 Gy; mean dose to the heart, <40 Gy; percentage of total
lung volume receiving ≥20 Gy (V20), <30%, dose to the
thoracic stomach, V40 ≤ 40–50%. Chemotherapy was intra-
venously administered using cisplatin at a dose of 30 mg
per square meter of body-surface area weekly. Chemother-
apy was initiated before radiation therapy on day 1 of eachweek of the therapeutic cycle. In parallel with concurrent
radiochemotherapy, the thymic peptide α1 was injected i.h.
at a dose of 1.6 mg per day for 3 weeks in order to retain
systematic immune function. Short-term curative effects
were evaluated based on the Response Evaluation Criteria
in Solid Tumors (RECIST) [25]. The short-term therapeutic
response was assessed based on the complete response
(CR) + partial response (PR). Adverse effects were evaluated
according to the Common Terminology Criteria for Ad-
verse Events (CTCAE) 3.0 (Grades 1–5). Acute radiation
injury was determined according to the Radiation Therapy
Oncology Group (RTOG) guidelines (Grades 0–4). Late ra-
diation injury was evaluated based on the RTOG/European
Organization for Research and Treatment of Cancer
(EORTC) criteria. If therapy was discontinued due to severe
toxicity, chemotherapy or radiotherapy was suspended until
recovery and the dose was reduced by 25% in the subse-
quent cycle.Follow-up
During the first year after treatment was completed, all
eligible patients were followed up every 3 months. Dur-
ing the second year, follow-up took place every 6
months, and then at the end of each year until 5 years
following treatment. The response assessment started
from the 3rd month after treatment, and patients were
followed up for at least 5 years or until death. Late toxic
effects, disease progression, and tumor-related death
were documented.
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Only 2 of the 98 patients were absent from our follow-
up assessments. The primary and secondary endpoints
were overall survival and severe morbidities of grade 2
or higher, respectively. Overall survival, the primary
endpoint, was calculated as the time interval from initi-
ation of treatment to death and was analyzed using the
Kaplan–Meier method. Significant differences were ana-
lyzed using the log-rank test. The t test and χ2 test were
optimized for quantitative and countable data, respect-
ively. All statistical analyses were performed using SPSS
13.0 statistics software (SPSS Inc., Chicago, IL, USA).
P < 0.05 was considered statistically significant.
Results
Response rates
In our study, the “response rate” denoted the ratio of
treated patients with CR + PR to the total number of eli-
gible patients. The response rate in group B (45/49,
91.8%) was significantly greater than that in group A
(36/49, 73.5%) (χ2 = 5.765, P = 0.016). In addition, group
B had a significantly lower presentation of stable disease
(SD) and progressive disease (PD) (4/49, 8.2%) as com-
pared with that of group A (13/49, 26.5%) (χ2 = 5.765,
P = 0.016).
Overall survival
For surviving patients, the median follow-up period was
60 months (range, 8–63). The intention-to-treat analyses
showed a median overall survival of 19 months in group
A versus 35 months in group B (P = 0.051 by the log-
rank test; hazard ratio, 0.76; 95% CI, 28–34) (Figure 1).
According to our outcomes, the therapeutic regimen,
radiation plus cisplatin-based chemotherapy, had anFigure 1 Comparison of the overall survival in both groups.impressive contribution to the survival benefit in pa-
tients with advanced locoregional ESCC (Table 2 and
Figure 1). Although there was no remarkable difference
in the overall survival rate at five years between both
groups (P = 0.051), the overall survival rates at 1 year
and 3 years in group B were significantly better than
those in group A (P = 0.032, P = 0.038) (Table 2).
Of the 49 patients in group B who underwent concur-
rent radiochemotherapy, 5 (10.2%) died from distant me-
tastases of ESCC as compared with 13 out of 49 patients
(26.5%) in group A (χ2 = 4.356, P = 0.036). Moreover, the
number of patients who died from locoregional progres-
sion of recurrent ESCC was 19 in group B versus 22 in
group A (χ2 = 0.676, P = 0.410).
Toxic effect of radiochemotherapy
No life-threatening toxic effects were observed in ei-
ther group, based on the observation that no radio-
chemotherapy-related deaths occurred in our study.
As shown in Table 3, the adverse effects in the
hematological and gastrointestinal systems in group B
were obviously more common than in group A. How-
ever, there was no significant difference between the
incidence of late adverse effects between both groups
(Table 3).
Multivariate analyses for prognostic factors
The prognostic factors for all recruited patients with
advanced locoregional ESCC are shown in Table 4.
Four risk factors, including GTV of radiation (≥5 cm3
versus <5 cm3), postoperative T stage (stage I/II versus
stage III/IV), locoregional recurrence of lymph node
metastases (≥2 versus <1), and chemotherapy treat-
ment (yes versus no) were characterized as significant
independent prognostic factors. Patients who had
small GTV, early postoperative T stage, small number
of locoregional recurrent lymph node metastases, and
chemotherapy treatment were likely to have a better
prognosis.
Discussion
With the increasing incidence of ESCC in Asia, it has
been reported that the recurrence rate of patients with







MS (Mo; 95% CI)
Group A 69.4 28.6 8.2 19 (14; 26)
Group B 85.7 46.9 14.3 35 (30; 40)
χ2 4.602 4.298 3.798
P 0.032 0.038 0.051
SR survival rate, MS median survival, Mo months.
Table 3 Treatment-related toxic effects
Group Acute toxicity ≥ grade 2 (n) Late toxicity (n)
Esophagitis Leukopenia Nausea and
vomiting








A 10 8 5 1 0 1 1 0
B 22 15 14 3 2 4 3 2
χ2 6.682 2.784 5.290
P 0.01 0.010 0.021 0.358* 0.495* 0.362* 0.242* 0.495*
*Fisher’s exact probability.
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and 11%, respectively, with a median survival time of
only 7 months [16,17]. Locoregional recurrence after
curative esophagectomy in patients with esophageal can-
cer remains a challenge to clinical oncologists, regardless
of the pathological type. The National Comprehensive
Cancer Network (NCCN) guidelines indicate that a
subgroup of patients with postoperative locoregional re-
currence may be able to tolerate concurrent radioche-
motherapy [9,16,26]. The limited survival benefit may
arise from the limited competence of the routine radi-
ation technique. With the disadvantage of localization
using 2-dimensional radiation fields, the radiation doses
for the targeted tumor in patients with locoregional
recurrent ESCC could not satisfy the demands of the
prescribed doses. Curative full-dose radiation may be
sacrificed partially to affect the radiation-related benefits
for the therapeutic regimen. In addition, inadequate
blood circulation and hypoxic situations following op-
erative implementation render the locoregional site to be
insensitive to radiotherapy [27].
An enhancement of virtual simulation is 3-DCRT, in
which the radiation beams are shaped to fit the target.
When the treatment conforms to the shape of the
tumor, the relative toxicity of radiation to the surround-
ing normal tissues is reduced, allowing a higher dose of
radiation to be delivered to the tumor than conventional
techniques allow [5,28,29]. With regard to limited
survival benefits from irradiation alone, concurrent ra-
diochemotherapy is expected to be another crux of treat-
ment for recurrent ESCC, which depends on the theory
that the tumor cell cycle phase is synchronized byTable 4 Multivariate analyses for prognostic factors in
both groups
β Sx χ2 P
GTV (<5 cm3 vs. ≥5 cm3) 1.452 0.343 6.673 0.003
Postoperative T stage
(I + II stage vs. advanced stage)
0.685 0.275 1.843 0.005
Regional recurrence of lymph
node metastases (=1 vs. >1)
0.021 0.004 1.016 0.002
Chemotherapy (Yes vs. No) 1.035 0.395 6.879 0.009
β: regression coefficient; Sx: standard error.chemotherapy, thus enhancing the sensitivity of radio-
therapy. Patients with resectable ESCC underwent pre-
operative neoadjuvant radiochemotherapy and had a
favorable outcome in the local control and a remarkable
clinical response rate.
Shioyama et al. [18] reported that a better overall sur-
vival is obtained for small recurrent lesions, radiation
doses more than 50 Gy, and patients with better health
scores. In another study, 85% (84/98) of recurrent medi-
astinal lymph node metastases were located around the
superior bronchus, the areas between the vessels of the
anterior mediastinum and the back of the tracheae, or
the inferior bronchus. Four risk factors, including the
GTV of radiation, postoperative T stage, locoregional re-
currence of lymph node metastases, and chemotherapy
treatment were characterized as significant independent
prognostic factors. The discrepancy may result from the
eligible criteria for patient recruitment. After effectively
protecting the spinal cord, lungs, stomach, and heart
from radiation, the target dose was appropriately in-
creased. Concurrent chemotherapy, administered by
low-dose cisplatin (30 mg per square meter of body sur-
face), was infused on day 1 of radiotherapy every week.
Although acute toxic effects, including esophagitis, nau-
sea, vomiting, and leukopenia, were observed in the
study, the therapeutic regimen was completed after the
patients received symptomatic treatment. Of note, no
life-threatening adverse effects were detected in either
group. These results indicated that our regimen for
patients with recurrent ESCC is well-tolerable. It was likely
that immunotherapy was simultaneously performed with
radiochemotherapy to preserve the immune system func-
tion that was impaired during the treatment. For locally ad-
vanced esophageal cancer, a significant improvement in
local control and overall survival was achieved with concur-
rent chemoradiotherapy as compared with radiotherapy
alone [11,14,30]. However, the incidence of local failure was
still as high as 44–54%. To improve these results, a phase
III trial comparing standard-dose radiotherapy (50.4 Gy)
and high-dose radiotherapy (64.8 Gy) concurrently com-
bined with 5-fluorouracil/cisplatin was conducted [27,30].
High-dose irradiation was adopted in our study. The overall
survival benefit in both groups in this study were in
Ma et al. Radiation Oncology 2014, 9:28 Page 6 of 7
http://www.ro-journal.com/content/9/1/28agreement with previous reports [6,14,21]. The findings
may be mainly attributed to the fact that all patients en-
rolled in this study showed no postoperative positive mar-
gins or locoregional lymph nodes metastases. Therefore,
the pathological CR + PR corresponded to the long-term
survival advantage. Of note, none of the eligible patients
underwent postoperative adjuvant chemotherapy or radio-
therapy, suggesting that the compliance to chemoradiother-
apy was warranted in order to preserve organ function.
However, it increased the recurrence risk, so the irradiation
doses could be appropriately elevated. In parallel, the total
duration of chemotherapy was likely to be shortened using
the therapeutic plan with low dose monotherapy. The ex-
posure dose to the OARs was sharply decreased by nonco-
planar 3D fields in the head-foot direction. Therefore, the
radiation dose was appropriately increased according to the
same normal tissue complication probability. A limitation
for our study was the relatively small sample size, which
may limit the study power.
Conclusions
In summary, the combined modality of 3-DCRT and
chemotherapy was well tolerated compared to radiation
alone and yielded superior overall survival rates in patients
with postoperative recurrence of mediastinal lymph node
metastases of ESCC. Further studies are needed to further
optimize this modality to benefit overall survival.
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